
## Xavier Kurz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7103728/publications.pdf Version: 2024-02-01



XAVIED KIIDZ

#	Article	IF	CITATIONS
1	Realâ€World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe. Clinical Pharmacology and Therapeutics, 2019, 106, 36-39.	2.3	180
2	Antidepressant use during pregnancy and risk of autism spectrum disorder and attention deficit hyperactivity disorder: systematic review of observational studies and methodological considerations. BMC Medicine, 2018, 16, 6.	2.3	87
3	EudraVigilance Medicines Safety Database: Publicly Accessible Data for Research and Public Health Protection. Drug Safety, 2018, 41, 665-675.	1.4	73
4	Measuring the impact of medicines regulatory interventions – Systematic review and methodological considerations. British Journal of Clinical Pharmacology, 2018, 84, 419-433.	1.1	62
5	Marketing Authorization Applications Made to the European Medicines Agency in 2018–2019: What was the Contribution of Realâ€World Evidence?. Clinical Pharmacology and Therapeutics, 2022, 111, 90-97.	2.3	58
6	Patient Registries: An Underused Resource for Medicines Evaluation. Drug Safety, 2019, 42, 1343-1351.	1.4	56
7	Relative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case–Control Study. Clinical Drug Investigation, 2019, 39, 205-213.	1.1	51
8	Association Between Peripheral Neuropathy and Exposure to Oral Fluoroquinolone or Amoxicillin-Clavulanate Therapy. JAMA Neurology, 2019, 76, 827.	4.5	49
9	Calcium channel blockers and cancer: a risk analysis using the UK Clinical Practice Research Datalink (CPRD). BMJ Open, 2016, 6, e009147.	0.8	47
10	Autoimmune disorders after immunisation with Influenza A/H1N1 vaccines with and without adjuvant: EudraVigilance data and literature review. Vaccine, 2012, 30, 7123-7129.	1.7	46
11	Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation. BMJ Open, 2018, 8, e023090.	0.8	40
12	Multiâ€centre, multiâ€database studies with common protocols: lessons learnt from the IMI PROTECT project. Pharmacoepidemiology and Drug Safety, 2016, 25, 156-165.	0.9	36
13	Considerations for pharmacoepidemiological analyses in the <scp>SARS oV</scp> â€₽ pandemic. Pharmacoepidemiology and Drug Safety, 2020, 29, 825-831.	0.9	36
14	Strengthening standards, transparency, and collaboration to support medicine evaluation: Ten years of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). Pharmacoepidemiology and Drug Safety, 2018, 27, 245-252.	0.9	33
15	Registries in European postâ€marketing surveillance: a retrospective analysis of centrally approved products, 2005–2013. Pharmacoepidemiology and Drug Safety, 2017, 26, 1442-1450.	0.9	32
16	Association between hydrochlorothiazide exposure and different incident skin, lip and oral cavity cancers: A series of populationâ€based nested case–control studies. British Journal of Clinical Pharmacology, 2020, 86, 1336-1345.	1.1	30
17	Increasing scientific standards, independence and transparency in postâ€authorisation studies: the role of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Pharmacoepidemiology and Drug Safety, 2012, 21, 690-696.	0.9	27
18	Regulatory and health technology assessment advice on postlicensing and postlaunch evidence generation is a foundation for lifecycle data collection for medicines. British Journal of Clinical Pharmacology, 2020, 86, 1034-1051.	1.1	26

XAVIER KURZ

#	Article	IF	CITATIONS
19	Safety monitoring of Influenza A/H1N1 pandemic vaccines in EudraVigilance. Vaccine, 2011, 29, 4378-4387.	1.7	22
20	Why we need more collaboration in Europe to enhance post-marketing surveillance of vaccines. Vaccine, 2020, 38, B1-B7.	1.7	20
21	The ADVANCE Code of Conduct for collaborative vaccine studies. Vaccine, 2017, 35, 1844-1855.	1.7	19
22	Barriers and Opportunities for Use of Patient Registries in Medicines Regulation. Clinical Pharmacology and Therapeutics, 2019, 106, 39-42.	2.3	17
23	Application of real-time global media monitoring and â€~derived questions' for enhancing communication by regulatory bodies: the case of human papillomavirus vaccines. BMC Medicine, 2017, 15, 91.	2.3	15
24	Indications for Systemic Fluoroquinolone Therapy in Europe and Prevalence of Primary-Care Prescribing in France, Germany and the UK: Descriptive Population-Based Study. Clinical Drug Investigation, 2018, 38, 927-933.	1.1	14
25	A European multicentre drug utilisation study of the impact of regulatory measures on prescribing of codeine for pain in children. Pharmacoepidemiology and Drug Safety, 2019, 28, 1086-1096.	0.9	13
26	Patterns of spontaneous reports on narcolepsy following administration of pandemic influenza vaccine; a case series of individual case safety reports in Eudravigilance. Vaccine, 2016, 34, 4892-4897.	1.7	12
27	Guidance for the governance of public-private collaborations in vaccine post-marketing settings in Europe. Vaccine, 2019, 37, 3278-3289.	1.7	12
28	Prescribing patterns of tramadol in adults in IMS® primary care databases in France and Germany between 1 January 2006 and 30 June 2016. European Journal of Clinical Pharmacology, 2019, 75, 707-716.	0.8	11
29	Can We Rely on Results From IQVIA Medical Research Data UK Converted to the Observational Medical Outcome Partnership Common Data Model?. Clinical Pharmacology and Therapeutics, 2020, 107, 915-925.	2.3	11
30	Antiepileptic drugs and risk of suicide attempts: a case–control study exploring the impact of underlying medical conditions. Pharmacoepidemiology and Drug Safety, 2017, 26, 239-247.	0.9	10
31	Effect of withdrawal of fusafungine from the market on prescribing of antibiotics and other alternative treatments in Germany: a pharmacovigilance impact study. European Journal of Clinical Pharmacology, 2019, 75, 979-984.	0.8	10
32	The ENCePP Code of Conduct: A best practise for scientific independence and transparency in noninterventional postauthorisation studies. Pharmacoepidemiology and Drug Safety, 2019, 28, 422-433.	0.9	10
33	What are the patients' and health care professionals' understanding and behaviors towards adverse drug reaction reporting and additional monitoring?. Pharmacoepidemiology and Drug Safety, 2021, 30, 334-341.	0.9	10
34	Assessing strength of evidence for regulatory decision making in licensing: What proof do we need for observational studies of effectiveness?. Pharmacoepidemiology and Drug Safety, 2020, 29, 1336-1340.	0.9	9
35	Imposed registries within the European postmarketing surveillance system: Extended analysis and lessons learned for regulators. Pharmacoepidemiology and Drug Safety, 2018, 27, 823-826.	0.9	8
36	Addendum to: Relative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case–Control Study. Clinical Drug Investigation, 2019, 39, 591-594.	1.1	6

XAVIER KURZ

#	Article	IF	CITATIONS
37	The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance: application to diabetes and vascular disease. British Journal of Diabetes and Vascular Disease, 2011, 11, 304-307.	0.6	5
38	Does additional monitoring status increase the reporting of adverse drug reaction <scp>s</scp> ? An interrupted time series analysis of <scp>EudraVigilance</scp> data. Pharmacoepidemiology and Drug Safety, 2021, 30, 350-359.	0.9	5
39	Advancing regulatory science, advancing regulatory practice. Pharmacoepidemiology and Drug Safety, 2017, 26, 722-726.	0.9	4
40	Ability of Primary Care Health Databases to Assess Medicinal Products Discussed by the European Union Pharmacovigilance Risk Assessment Committee. Clinical Pharmacology and Therapeutics, 2020, 107, 957-965.	2.3	3
41	Collection of Data on Adverse Events Related to Medicinal Products: A Survey Among Registries in the ENCePP Resources Database. Drug Safety, 0, , .	1.4	2
42	Increasing the impact of Post Authorisation Safety Studies: transparency is key. European Journal of Internal Medicine, 2021, 83, 6-7.	1.0	1
43	International Collaboration in Realâ€World Evidence Generation for Direct Acting Oral Anti oagulants. Clinical Pharmacology and Therapeutics, 2021, 109, 299-301.	2.3	1
44	Authors' Reply to Ravi Jandhyala's Comment on "Patient Registries: An Underused Resource for Medicines Evaluation: Operational Proposals for Increasing the Use of Patient Registries in Regulatory Assessments― Drug Safety, 2019, 42, 1517-1518.	1.4	0